![Coloured compounds may help coronavirus evade antibodies](http://www.imperial.ac.uk/ImageCropToolT4/imageTool/uploaded-images/newseventsimage_1619170978786_featurenews2012_x1.jpg)
![shadow](http://www.imperial.ac.uk/assets/news/img/image_shadow_sidebar.png)
Hide and seek
Coloured compounds may help coronavirus evade antibodies
Pigments in the body which give bruises their green and yellow hues may help coronaviruses hide from the immune system.
Coloured compounds may help coronavirus evade antibodies
Pigments in the body which give bruises their green and yellow hues may help coronaviruses hide from the immune system.
UK researchers identify inflammatory protein linked to severe COVID-19
Patients with severe COVID-19 show increased levels of a key protein in their blood, which researchers believe may help identify those most at risk.
New study to explore how well COVID-19 vaccines protect dialysis patients
A new study will assess how well COVID-19 vaccines work in people who attend hospital for their dialysis treatment (haemodialysis).
10 times Imperial made us smile in 2020
This year has been far from typical, but Imperial College London has created some rainbows amongst the clouds.
1
COVID-19 immunity lasts over 4 months, but antibody and T cells can “uncouple"
Majority carry neutralizing antibodies 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection, but antibody and T cell responses can "uncouple".
2
Feature
Q&A: Cold chains, COVID-19 vaccines and reaching low-income countries
Many low-income countries lack the infrastructure to deliver vaccines effectively, so how can we ensure COVID-19 vaccines are accessible for all?
3
New anti-cancer drug combo treatment shows promise for myeloma patients
Phase 3 trial results reveal that selinexor – a relatively new anti-cancer drug – improves patient outcomes when combined with established treatments.
Cannabis pain insights and kidney disease discoveries: News from the College
Here’s a batch of fresh news and announcements from across Imperial.
2
UK researchers to explore human challenge studies for COVID-19
Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.
Bacteria-fighting cells in the airways boost infection risk from viruses
Having more bacteria-fighting immune cells in the nose and throat may explain why some people are more likely to be infected by respiratory viruses.